Understanding Trauma And Support In Clinical Trials

Clinical trials in rare disease and oncology settings demand more than scientific precision—they require a trauma-informed, patient-first mindset. Families navigating chronic, progressive illnesses often carry emotional burdens that shape how they engage with trials. Missed visits, protocol challenges, and emotionally driven decisions are common when trauma is unaddressed. Hypervigilance, a frequent trauma response, can skew data quality and complicate trial outcomes. Building trust is essential, especially in communities that have historically faced limited transparency and access. For many, trial participation—such as in Duchenne muscular dystrophy—represents both hope and hardship, requiring lifestyle shifts and emotional resilience. Understanding these dynamics is key to designing trials that are not only scientifically sound but also truly patient-centered.

Access the full article to explore how trauma-informed strategies can improve trial design and engagement.